• Follow the Money: Trials for Major Depressive Disorder Therapies, Kidney Disease Treatment, More

    Clinical Research News | Seaport Therapeutics plans to advance their therapeutic candidate SPT-300, an oral prodrug of allopregnanolone; Purespring Therapeutics will initiate a clinical trial for IgAN, a common, chronic kidney disease primarily affecting young adults; and more.

    Oct 29, 2024

  • Advancing Health Equity: Community-First Approach to Drive Diversity in Clinical Research

    Clinical Research News | In clinical research, one ongoing challenge continues to persist: a lack of diverse representation. While the root cause stems from a combination of limited access and endemic mistrust of the health care system among certain communities, the outcome is that large pockets of communities are often excluded from studies, even in key areas where they are disproportionately affected by diseases such as diabetes, heart disease, and certain forms of cancer.

    Oct 25, 2024

  • SCOPE Europe 2024 Best of Show Entries

    Clinical Research News | The results are in: there are twelve new product finalists in the 2024 SCOPE Europe Best of Show awards that will be on display next week in Barcelona. Starting at the opening reception, the SCOPE Europe community is invited to identify exceptional innovation in technologies used by life science professionals, voting on the most impactful new products of the year.

    Oct 24, 2024

  • Drug Developers Eying Rollout of AI Legislation in the EU

    Clinical Research News | Eyes around the globe are on the EU Artificial Intelligence (AI) Act—the first comprehensive legal framework on AI anywhere—which will likely influence the direction of regulatory oversight measures adopted elsewhere, include other major markets such as the United States. Differing perspectives on the Act, including if and to what extent it could be a “death knell” for innovation, will be aired during a panel discussion being staged at the upcoming Summit for Clinical Ops Executives (SCOPE) Europe in Barcelona, Spain.

    Oct 22, 2024

  • Estrogen’s Impact on Cancer Reveals New Treatment Options

    Clinical Research News | A groundbreaking new approach for treating triple-negative breast cancer is moving forward, thanks to discoveries from Dr. Donald McDonnell’s lab at Duke University. Traditionally, hormone therapies have only been considered effective for estrogen receptor-positive cancers, but McDonnell’s research suggests that estrogen modulation could also impact TNBC.

    Oct 17, 2024

  • Psst! Need a Simple and Reliable Eye Tracker for Your Brain Studies?

    Clinical Research News | A mechanical engineer at the University of Houston is seeking physician collaborators with a research need for a small but sensitive wearable eye-tracking system to provide continuous data on human brain activity. The need was suggested by a survey of the literature, which found that a shortage of data coming from devices used in supervised clinical settings was resulting in inconclusive correlations study after study.

    Oct 15, 2024

  • Catching Up With Jill Pellegrino, Now Leading AutoCruitment

    Clinical Research News | For as long as most people can remember, patient enrollment into clinical trials has been abysmal—so much so that 80% of studies don’t finish on time and 55% end due to low accrual rates. The underlying issue is overreliance on study sites to find participants on their own.

    Oct 10, 2024

  • CluePoints Launches Medical & Safety Review (MSR) Software

    Clinical Research News | CluePoints has launched its Medical & Safety Review (MSR) tool that aims to simplify and streamline the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history.

    Oct 9, 2024

  • Curing Data Collection Woes Could Take a Village

    Clinical Research News | The average clinical trial generates three times as much data as it did a decade ago, and yet there are no standards in place for how that information should be collected. That’s a big problem for many reasons, not the least of which is that drug developers may be missing key insights about the way interventions are working in individuals and across populations.

    Oct 8, 2024